Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1652130
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Intellia Therapeutics filed an 8-K, but the details are sparse.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting an event under "Other Events." The filing does not contain specific details about the event, dollar amounts, or names beyond the company's standard information.
Why It Matters
This filing indicates a material event has occurred for Intellia Therapeutics, Inc., but the specific nature and impact require further investigation of the full document.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no immediately apparent negative or positive financial or operational information disclosed.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- October 29, 2025 (date) — Date of earliest event reported
- 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (address) — Principal executive offices
FAQ
What specific event is reported under "Other Events" in this 8-K filing?
The provided text does not specify the nature of the event reported under "Other Events."
When was the earliest event reported in this filing?
The earliest event reported was on October 29, 2025.
What is the principal executive office address for Intellia Therapeutics, Inc.?
The principal executive office is located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the SEC file number for Intellia Therapeutics, Inc.?
The SEC file number is 001-37766.
What is the IRS Employer Identification Number (EIN) for Intellia Therapeutics, Inc.?
The EIN is 36-4785571.
Filing Stats: 1,013 words · 4 min read · ~3 pages · Grade level 17.4 · Accepted 2025-10-29 16:22:38
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d98865d8k.htm (8-K) — 28KB
- 0001193125-25-256378.txt ( ) — 140KB
- ntla-20251029.xsd (EX-101.SCH) — 3KB
- ntla-20251029_lab.xml (EX-101.LAB) — 18KB
- ntla-20251029_pre.xml (EX-101.PRE) — 11KB
- d98865d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for "nex-z" (also known as NTLA-2001), including the ability resolve the clinical hold on nex-z and to resume and successfully complete its MAGNITUDE and MAGNITUDE-2 trials for nex-z. Any forward-looking statements in this current report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainty as to when the clinical hold may be resolved, including the actions or studies that the Company may be required to take or conduct in order to resolve the clinical hold ; uncertainties related to Intellia's ability to resume the MAGNITUDE and MAGNITUDE-2 trials, the implications of the clinical hold on the safety and efficacy of nex-z and further development of nex-z; regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncer
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Intellia Therapeutics, Inc. (Registrant) Date: October 29, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President